Wednesday - May 7, 2025
MOBILE, Ala. / Nov 09, 2023 / Business Wire / CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced that management will participate in the Stephens 2023 Annual Investment Conference to be held November 14-16, 2023, at The Grand Hyatt in Nashville, Tennessee.
The fireside chat presentation by Chris Fowler, president and chief executive officer, will begin at approximately 8:00 a.m. Central Time on Thursday, November 16, 2023, and will be available to investors via a live audio webcast. A link to the broadcast can be found at the investor relations section of the Company’s website www.cpsi.com.
About CPSI
CPSI has over four decades of experience in connecting providers, patients and communities with innovative solutions that support both the clinical and financial side of healthcare delivery. We provide business, consulting, and managed information technology (IT) services, including our industry leading HFMA Peer Reviewed® suite of revenue cycle management (RCM) offerings, to help streamline day-to-day revenue functions, enhance productivity, and support the financial health of healthcare organizations. Our patient engagement solutions provide patients and providers with the critical information and tools they need to share existing clinical data and analytics that support value-based care, improve outcomes, and increase patient satisfaction. We support efficient patient care across an expansive base of community hospitals and post-acute care facilities with electronic health record (EHR) product offerings that successfully integrate data between care settings. We make healthcare accessible through data-driven insights that support informed decisions and deliver workflow efficiencies, while keeping patients at the center of care. We are a healthcare solutions company. We clear the way for care. For more information, please visit www.cpsi.com.
Last Trade: | US$25.65 |
Daily Change: | -0.64 -2.43 |
Daily Volume: | 78,296 |
Market Cap: | US$382.950M |
March 10, 2025 February 12, 2025 February 11, 2025 January 30, 2025 January 02, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load